Interleukin-7 and -15 maintain pathogenic memory Th17 cells in autoimmunity.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27899224)

Published in J Autoimmun on November 26, 2016

Authors

Yihe Chen1, Sunil K Chauhan1, Xuhua Tan1, Reza Dana2

Author Affiliations

1: Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
2: Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA. Electronic address: reza_dana@meei.harvard.edu.

Articles cited by this

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49

Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol (2003) 15.51

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol (2000) 12.81

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89

Homeostasis of naive and memory T cells. Immunity (2008) 7.48

Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med (2002) 7.11

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007) 6.19

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63

Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med (2007) 5.58

TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41

Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med (2002) 5.09

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53

Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol (2002) 4.36

Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol (2003) 3.82

Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med (2003) 3.76

Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol (2007) 3.53

T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med (2007) 3.29

Gamma chain required for naïve CD4+ T cell survival but not for antigen proliferation. Nat Immunol (2000) 3.10

Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med (2002) 3.06

IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol (2009) 2.65

Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37

Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med (2007) 2.29

IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood (2007) 2.24

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23

Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol (2009) 2.19

Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99

Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med (2007) 1.99

IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci U S A (2004) 1.79

Generation and maintenance of memory CD4(+) T Cells. Curr Opin Immunol (2009) 1.50

Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol (2003) 1.37

CD4 memory T cells: what are they and what can they do? Semin Immunol (2009) 1.29

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2014) 1.28

A novel pro-lymphangiogenic function for Th17/IL-17. Blood (2011) 1.08

The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. J Immunol (2012) 1.04

Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. Immunity (2015) 1.03

Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep (2013) 1.01

IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis. Genes Immun (2010) 0.97

Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol (2010) 0.96

Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol (2013) 0.95

Long-lived colitogenic CD4+ memory T cells residing outside the intestine participate in the perpetuation of chronic colitis. J Immunol (2009) 0.92

Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther (2012) 0.88

Evidence of STAT5-dependent and -independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation. Immunol Cell Biol (2009) 0.80

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget (2015) 0.79